Exclusive

Publication

Byline

Location

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event – MOVE-Lp(a)

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More


Singapore Clinical Trial: GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells'. The f... Read More


Singapore Clinical Trial: A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Sa... Read More


Singapore Clinical Trial: A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants wi... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Effica... Read More


Singapore Clinical Trial: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More


Singapore Clinical Trial: A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bev... Read More


Singapore Clinical Trial: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More


Singapore Clinical Trial: A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherap... Read More


Singapore Clinical Trial: A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LY4226695 in healthy participants.

Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharma... Read More